Efficacy of targeted therapy for lung cancer patients included in IMPRESS-Norway, and precision cancer medicine in hard-to-treat rare cancers in the MATRIX-RARE study.
Myhre PL, Helland Å, Myhr KM, Skogås JG, Langø T, Goll R, Vikse J, Fretland SØ(2026) NorTrials drives growth in Norwegian clinical trials Tidsskr Nor Laegeforen, 146(1) DOI 10.4045/tidsskr.25.0685, PubMed 41556676
Van der Pol H, Kringelbach T, Martin Agudo M, Bratseth Stav G, Fagereng GL, Fiocco M, Sørum Falk R, Homer V, Haj Mohammad S, Timmer H, Verlingue L, Helland Å, Rohrberg K, Lassen U, Halford S, Jalkanen K, Juslin T, Krebs MG, Oliveira J, Baltruskeviciene E, Ojamaa K, Taskén K, Gelderblom H(2026) Procedures of data merging in precision cancer medicine: the PRIME-ROSE project Acta Oncol, 65, 1-8 DOI 10.2340/1651-226X.2026.44889, PubMed 41496458
Nassar AH, Bou Farhat E, Abushukair H, Alchoueriy M, Salem S, Machaalani M, Adib E, Henske EP, Babu P, Choueiri TK, Rakaee M, Busund LR, Takabe Y, Lau SF, Rall K, Naqash AR, Jansen C, Wang X, Challa P, Tarantino P, Partridge AH, Tolaney SM, Kwiatkowski DJ, Winer EP(2025) Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer J Natl Cancer Inst(in press) DOI 10.1093/jnci/djaf344, PubMed 41418409
